Management of inflammatory bowel disease in the elderly: do biologicals offer a better alternative?

摘要: The management of inflammatory bowel disease (IBD) in elderly patients provides added complexity for healthcare providers who need to take into account the high likelihood co-morbid disease, polypharmacy and, many instances, greater patient fragility. While biologics are often considered first-line corticosteroid-sparing strategies moderate severe additional variables unique an warrant consideration when discussing IBD therapeutics. As chronic corticosteroid use, although relatively common among older patients, is suboptimal, efficacy and safety compared with immunomodulators needs investigation.